Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

We published a story: “Patient centricity at Astellas—all about action.”

11/30/2021 | 01:21am EST

A team dedicated to patient centricity within a pharmaceutical company may seem redundant. After all, it should be a given that a company focused on drug discovery, development and delivery to address the health needs of patients would be, by its very nature, patient centric.

However, the concept of "medical value" has always been open to interpretation. This has often resulted in one-size-fits-all standardized concepts of treatment, and situations where the "success" of a new drug was judged in the research lab and not a real-world setting.

As a clinical medicine practitioner, Anthony spent more than twelve years treating patients daily. This wealth of experience in the examination room put him in the position of understanding what matters most to his patients on a holistic level. For example, he recalls a situation when he was asked by another medical professional to share his opinion on the meaning of medical value. He said, "My opinion means absolutely zero, because my opinion is one person. What we need to do is to create an opportunity for patients themselves to let us know."

Fast-forward over a decade and the pharmaceutical industry is now taking note. Anthony states, "Companies realized that if we aren't talking about patient centricity, we're the outliers." But the talk must lead to an actionable outcome. "It's easy to talk about. It's even easy to have a team meet patients and write down their information." But the question is, what do you do with that information? "How do you change a company infrastructure to accommodate a new decision tree when it comes to discovering, developing and delivering new medicines, and understanding their potential value?"

Meaningful patient centricity is difficult to define. It is a fluid concept affected by both the healthcare landscape and the ever-changing emotions and behaviors of patients and their caregivers. Understanding and adapting to the shifting environments and behaviors is a key to creating a meaningful patient-centric culture. COVID-19 and the rise in digital healthcare have both altered the landscape and revealed an essential element of patient centricity that often gets overlooked-treatment versus care.

COVID-19 has shaken up mindsets and behaviors once thought to be set in stone. The tragedy of the pandemic pushed pharmaceutical companies to act in unprecedented ways. Anthony states that COVID-19 demonstrated "breakthroughs can happen fast when drug companies and regulators listen to, and communicate openly with, patients."

While the healthcare response to the unprecedented COVID-19 pandemic has in many ways been exceptional, the pandemic has in other ways negatively affected patient care for non-COVID-19 conditions such as cancer. For example, patients have been forced to go through treatments alone without the support of caregivers and be diagnosed with life-altering illnesses through computer screens. While these situations may be unavoidable, it is important to understand and address the anxiety and stress caused by such changes.

This is the crux of treatment versus care. Anthony explains that "treatment is delivering a medicine, and we're very good at it in the pharmaceutical world. What we have not yet perfected is also understanding the issues that are affecting a patient in their real-world environment outside of the treatment that we're delivering, like anxiety or fatigue."

The rise in digital healthcare provides opportunities to address this. If utilized properly, wearable digital technology can offer insight into patients' emotions and lifestyles that would potentially be "a huge leap forward in delivering care versus treatment." However, as in every aspect of a patient-centric approach, we have to be very thoughtful, careful, and make sure that we respect the patient and their privacy; that they fully understand everything prior to using a wearable device is essential.


Astellas Pharma Inc. published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 06:20:11 UTC.

ę Publicnow 2021
01/16Glenmark Pharmaceuticals Unit Gets US FDA's Approval for Regadenoson Injection
01/10Basilea Pharmaceutica - Strong Cresemba (isavuconazole) sales by Astellas in the U.S. t..
01/10Modalis Therapeutics and Astellas Pharma End Research Collaboration on Nervous System M..
01/07Basilea To Get $16 Million From Astellas After Strong Antifungal Drug Sales In US
01/07Strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF 15 million..
01/07Modalis Announces Termination of Research Collaboration on MDL-204
01/06Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration ..
2021Japanese shares end higher on Wall St boost, airlines shine
2021Japanese shares track Wall Street higher, Omicron concerns weigh
2021Nikkei ends 2% higher on bargain-buying, led by tech shares
More news
Sales 2022 1 328 B 11 592 M 11 592 M
Net income 2022 183 B 1 602 M 1 602 M
Net cash 2022 380 B 3 318 M 3 318 M
P/E ratio 2022 19,6x
Yield 2022 2,59%
Capitalization 3 572 B 31 177 M 31 190 M
EV / Sales 2022 2,40x
EV / Sales 2023 2,13x
Nbr of Employees 15 455
Free-Float -
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 928,00 JPY
Average target price 2 451,67 JPY
Spread / Average Target 27,2%
EPS Revisions
Managers and Directors
Kenji Yasukawa Executive Officer
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811